Protocolo de tratamiento de Covid 19 en Hospital Miguel H. Alcívar -Bahía de Caraquez-Manabí

Bosco Fabian Mendoza-Cedeño, María Belén Cedeño-Reyes, Shirley Mariuxi Loor-Moncayo, Héctor Paul Mera-Resabala, Diego Humberto Moreira-Mendoza, Juliana Estefania Moncayo-Farias

Resumen


Varios países del mundo desde que inicio la pandemia por SARSCOV 2 han intentado establecer diferentes protocolos de salud en el manejo y tratamiento, el objetivo principal de esta investigación se vislumbra hacia develar los protocolos de tratamiento de COVID 19 en Hospital Miguel H. Alcivar -Bahia de Caraquez-Manabi, la presente investigación se desarrolló bajo el  enfoque de investigación de tipo documental; se realizó una revisión de material bibliográfico sobre el COVID-19, haciendo uso del método descriptivo analítico, tomando en cuenta los estudios observacionales. Entre los resultados y discusiones se puede decir en torno a los análisis comparativos cuando se compara la muestras del tracto respiratorio superior vs el esputo, quedo demostrado que tiene mejor  redito el esputo al momento del diagnóstico, protocolo estándar utilizado en el Hospital de Bahía de Caraquez en la cual ha seguido con los protocolos de tratamientos ya establecidos en otros países, además se ha agregado la aplicación de un fármaco inhibidor oral de los receptores de la tirosina quinasa asociadas a las proteínas Janus (JAK) JAK1 y JAK2 denominado Ruxolitinib. El cual ha demostrado buena tolerancia en los pacientes Covid 19; con mínimos efectos adversos, resaltando una disminución de la mortalidad en pacientes hospitalizados.


Palabras clave


Ruxolitnib; Covid 19; severo; mortalidad; tratamiento

Texto completo:

PDF HTML XML

Referencias


.-Worldometer, COVID-19 Coronavirus Pandemic, Last updated: June 20, 2020, 20:35 GMT

2. .-Who Coronavirus disease (COVID-19), Situation Report 152, Data as received by WHO from national authorities by 10:00 CEST, 20 June2020.

3.- Ministerio de Salud Pública del Ecuador, Situación Nacional por COVID-19 (CORONAVIRUS) Inicio 29/02/2020-Corte 19/06/2020 08:00 -INFOGRAFÍA N°113.

4.- https://news.un.org/es/story/2020/07/1477691?Boletin Informativo 20 de Julio 2020, Consultado 25 Agosto 2020.

5.- Instituto de salud Global Barcelona https://www.isglobal.org/covid-19-novedades-cientificasEvidencia publicada entre el 28/08/2020 y el 1/09/2020.

6.Sebastiao Moreira (EFE), disponible en: https://www.elperiodico.com/es/ciencia/20200410/resultados-estudios-cientificos-coronavirus-7897426.

7 The epidemiology, diagnosis and treatment of COVID-19, International Journal of Antimicrobial Agents 55(2020) 105955

8.- Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowd sourced data: a population-level observational study, www.thelancet.com/digital-health Vol 2 April 2020

9.- Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission, Aliment PharmacolTher. 2020;51:843–851

10.- Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1, n engl j med 382;16nejm.orgApril 16, 2020

11.- Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany, n engl j med 382;10 nejm.org March 5, 2020

12.- Asymptomatic cases in a family cluster with SARS-CoV-2 infection,www.thelancet.com/infection, Vol 20 , April 2020

13.- Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission, Aliment PharmacolTher. 2020 May; 51(9): 843–851.

14.- Anosmia and Ageusia: Common Findings in COVID-19 Patients, Laryngoscope, 00:1, 2020, The American Laryngological,Rhinological and Otological Society, Inc.

15.- Laboratory testsand outcome for patients with COVID-19: A systematic review and meta-analysis, The Journal of Applied Laboratory Medicine, jfaa098, https://doi.org/10.1093/jalm/jfaa098, Published: 23 June 2020

16 Association of inflammatory markers with the severity of COVID-19: A meta-analysis, F. Zeng et al. / International Journal of Infectious Diseases 96 (2020) xxx–xxx

17.-Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019, Clinical Infectious Diseases 1 /4/2020.

18- Performance of oropharyngeal swab testing comparedto nasopharyngeal swab testing for diagnosis of COVID-19 —United States, January-February 2020, Clinical Infectious Diseases, ciaa759, https://doi.org/10.1093/cid/ciaa75 16 June 2020

19. Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia, ClinChem Lab Med 2020; 58(7): 1089–1094.

20.-Guiadance on interpretation covid 19 test results ; CDC, 2020

21.- Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019, Clinical Infectious Diseases 1 /4/2020.

22 Martinez, M, Briones R, Cortes J. (2013)-Metodología de la investigación para el área de la salud, segunda edición por,

McGRAW-HILL INTERAMERICANA EDITORES S.A. DE C.V.

23 Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia, ClinChem Lab Med 2020; 58(7): 1089–1094

24.- Factors Associated With Prolonged Viral RNAShedding in Patients with Coronavirus Disease 2019(COVID-19), Correspondence| Volume 20, ISSUE 4, P411-412, April 01, 2020

25.- Swabs Collected by Patients or Health Care Workers for SARS-CoV-2 Testing, The New England Journal of Medicine, June 8, 2020.

26.- Role of serology in the COVID-19 pandemic / clinical infectious diseases 2/05/2020

Sean Stowell, MD, PhD Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta

27.- Imaging of Coronavirus Disease 2019: A Chinese Expert Consensus Statement Eur J Radiol. 2020 Apr 18 : 109008,

28.-Eur J Radiol. 2020 Apr 18 : 109008 , Imaging of Coronavirus Disease 2019: A Chinese Expert Consensus Statement

29.- Correlation of Chest CT and RT-PCR Testing in CoronavirusDisease 2019 (COVID-19) in China: A Report of 1014 Cases, Radiology2020 Feb 26;200642.doi: 10.1148/radiol.2020200642. Online ahead of print,

30.- Can Chest CT Features Distinguish Patients With Negative From Those With Positive Initial RT-PCR Results for Coronavirus Disease (COVID-19)?, American Journal of Roentgenology: 1-5. 10.2214/AJR.20.23012.

31.- Coronavirus Disease 2019 (COVID-19),Treatment Guidelines, National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/.

32.- https://www.mayoclinic.org/es-es/diseases-conditions/coronavirus/symptoms-causes/syc-20479963 pagina en línea Disponible 20 de Agosto 2020.

33.- Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID 19, last updated June 25 , 2020 and posted online at www.idsociety.org/covid19guidelines.

34.- Coronavirus Disease 2019 (COVID-19),Treatment Guidelines, National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/.

35.- symptom – bases strategy to discontinue isolation for persons with Covid 19, CDC, update may 3, 2020

36.- Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19, n engl j med 382;25 nejm.org June 18, 2020.

37.- Antiviral treatment of COVID-19, Turk J Med Sci. 2020; 50(3): 611–619.

38.-Remdesivir for the Treatment of Covid-19 — Preliminary Report, This article was published on May 22, 2020, at NEJM.org

39.- Compassionate Use of Remdesivir for Patients with Severe Covid-19, N Engl J Med 2020;382:2327-36

40.- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19, N Engl J Med 2020;382:1787-99

41.- Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review, Journal of Clinical Virology 127 (2020) 104380

42.- Outcomes in Patients with Severe COVID-19 Disease Treated with Tocilizumab – A Case- Controlled Study, An International Journal of Medicine, hcaa206, https://doi.org/10.1093/qjmed/hcaa206, 19 June 2020

43.- Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19, AGING 2020,Vol.12,No. 8

44.- convalescent plasma for covid 19. A randomized clinical trial, medRxiv preprint doi: https//doi.org/10.1101/2020.07.01.20139857

45.-Ruxolitinib in treatment of severe coronavirus disease 2019 ( covid 19 ): a multicenter, single – blind, randomized trial. Pre – proof, journal of allergy and clinical immunology.

46.- Title: The role of corticosteroids in the management of critically ill patients with coronavirus disease 2019 (COVID-19): A meta-analysis, medRxiv preprint doi: https://doi.org/10.1101/2020.04.17.20069773.this version posted April 22, 2020

47.- Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial, www.thelancet.com/respiratory Vol 8 March 2020

48.- Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19), Intensive Care Med https://doi.org/10.1007/s00134-020-06022-5

49.- Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study, www.thelancet.com/respiratory Published online June 19, 2020 https://doi.org/10.1016/S2213-2600(20)30268-X

50.- Infectious Diseases Society of America/AmericanThoracic Society Consensus Guidelines on theManagement of Community-Acquired Pneumoniain Adults, CID 2007:44 (Suppl 2)•S27

51.-https://www.healthychildren.org/Spanish/health-issues/conditions/COVID-19/Paginas/2019-Novel-Coronavirus.aspx consultado 25 Agosto 2020.




DOI: https://doi.org/10.23857/pc.v5i9.1784

Enlaces de Referencia

  • Por el momento, no existen enlaces de referencia
';

Bookmark and Share




Polo del Conocimiento              

Revista Científico-Académica Multidisciplinaria

ISSN: 2550-682X

Casa Editora del Polo                                                 

Manta - Ecuador       

Dirección: Ciudadela El Palmar, II Etapa,  Manta - Manabí - Ecuador.

Código Postal: 130801

Teléfonos: 056051775/0991871420

Email: polodelconocimientorevista@gmail.com / director@polodelconocimiento.com

URL: https://www.polodelconocimiento.com/